n/a
Abstract Title:

Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.

Abstract Source:

AIDS. 2019 Oct 16. Epub 2019 Oct 16. PMID: 31651429

Abstract Author(s):

Giada Sebastiani, Sahar Saeed, Bertrand Lebouche, Alexandra de Pokomandy, Jason Szabo, Louis-Patrick Haraoui, Jean-Pierre Routy, Philip Wong, Marc Deschenes, Peter Ghali, Marina Klein,

Article Affiliation:

Giada Sebastiani

Abstract:

OBJECTIVE: Human immunodeficiency virus (HIV)-infected patients are at increased risk of nonalcoholic steatohepatitis (NASH). Vitamin E is recommended for treatment of NASH in the general population. However, its safety and efficacy among HIV-infected patients remain unknown.

DESIGN: Single centre, phase IV, open-label, single arm clinical trial.

METHODS: HIV mono-infected patients without significant alcohol intake or viral hepatitis coinfection were included. The diagnosis of NASH was based on the co-existence of fatty liver, diagnosed by controlled attenuation parameter (CAP)≥ 248 dB/m, and significant hepatocyte apoptosis, defined by the serum biomarker cytokeratin 18 (CK-18)>130.5 U/L. Participants were treated with 800 IU daily of oral vitamin E (alpha-tocopherol) for 24 weeks, and followed for an additional 24 weeks post-discontinuation. Generalized linear mixed effects models were used to evaluate changes in ALT, CAP and CK-18 at the completion of treatment and end of follow-up, controlling for pre-treatment trends.

RESULTS: A total of 27 patients were included. Four (15%) had a pretreatment liver biopsy, which confirmed the diagnosis of NASH in all cases. Compared to baseline, 24 weeks of vitamin E treatment improved ALT (-27 units/L; 95% confidence interval [CI] -37, --17), CAP scores (-22 dB/m; 95% CI -42, -1) and CK-18 (-123 units/L; 95% CI -201, -46). Conversely, there was no change in BMI. No serious adverse event was reported and no patient was lost to follow-up.

CONCLUSION: In this first clinical trial, we showed that vitamin E is an effective and well-tolerated treatment for NASH in HIV-infected patients.

Study Type : Human Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.